Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-Therapy.
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Merck & Co
- 05 Jun 2009 Actual patient number (8) added as reported by ClinicalTrials.gov.
- 04 May 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Sep 2007 New trial record.